tuberculous pleurisy
Conditions
Interventions
Group A:prednisone:orally taken 30 mg once daily for two weeks, then reduce to 20 mg once daily for 3th week
finally reduce to 10 mg for 4th week
Group B:Placebo:orally taken 30 mg once daily for two weeks, then reduce to 20 mg once daily for 3th week
Sponsors
Wuhan Union Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. To be aged 18 to 65 years; Male or female; 2. Presented with typical clinical features and signs suggesting pleurisy; 3. Willing to join this study and sign informed consent form; 4. Consisten;t with the diagnosis criteria in patients with tuberculous pleurisy.
Exclusion criteria
Exclusion criteria: 1. Severe cardiac diseases,lung diseases, hematological diseases, malignant tumor, hypoimmunity diseases, mental diseases, diabetes; 2. digestive system diseases,such as peptic ulcer or alimentary tract hemorrhage; 3. Abnormal of blood-fasting sugar or postprandial blood sugar(2 hours); 4. Chronic liver diseases,such as viral hepatitis type B or C; 5. Chronic hepatic or renal inadequacy (ALT>1.5 upper limits of normal;Cr>upper limits of normal); 6. Alcohol or drug abuse; 7. Package chest or pachynsis pleurae; 8. The course of disease >14 days; 9. Anti-tuberculosis therapy >30 days; 10. Woman with pregnant or lactation; 11. Have accepted glucocorticosteroid; 12. Participate in other clinical trials within three weeks; 13. Contraindication to glucocorticosteroid.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| time of pleural thickening;time of pleural effussion absorptionsorption; | — |
Primary
| Measure | Time frame |
|---|---|
| time of pleural thickening; | — |
Countries
China
Contacts
Public ContactHuangzhong Shi
Outcome results
None listed